Articles related to Endocrinology, Diabetes, Metabolism

The FDA approved a low-estrogen weekly contraceptive patch for pregnancy prevention in eligible women with BMI below 30 kg/m². Approval was supported by Phase 3 efficacy, safety, and adhesion data, but use remains subject to established combined hormonal contraceptive contraindications.

U.S. News expanded its 2026-2027 hospital rankings with new regional specialty evaluations in cancer and cardiovascular care while increasing recognition for regional hospitals. Rankings continued to emphasize risk-adjusted mortality, preventable complications, patient experience, and objective outcomes measures.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

The 2026 ACC/AHA dyslipidemia guideline reintroduces LDL-C treatment targets, expands risk assessment, and recommends universal Lp(a) screening. New analyses suggest many US adults now exceed recommended cholesterol thresholds, although treatment decisions remain individualized.

Two prospective cohorts found that metabolically unhealthy adults generally had higher dementia risk estimates regardless of obesity status. Metabolically healthy obesity was not associated with increased dementia risk in primary analyses, though findings varied across sensitivity analyses.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.